OBJECTIVE: To evaluate the antimicrobial susceptibility pattern of @entity6101 susceptible (OSSA) and resistant @entity794 (ORSA) isolates to other antimicrobial agents that can be used for the treatment of @entity1793 . MATERIAL AND METHOD: We evaluated 117 clinical @entity794 isolates from several S  o Paulo hospitals. Clinical isolates from Campinas, SP and from Jo  o Pessoa, PB, were also included. The in vitro susceptibility testing was performed by broth microdilution as described by the National Committee for Clinical Laboratory Standards (NCCLS). The minimum inhibitory concentration (MIC) was evaluated for 24 antimicrobial agents, including @entity7660 , @entity2887 , @entity581 , @entity48094 , @entity7187 , @entity35995 and streptogramins. Both commercially available and experimental drugs were included in the study. Cross-resistance among @entity2887 was evaluated by susceptibility testing 24 isolates to 10 @entity2887 . RESULTS: The antimicrobial agents that showed the highest in vitro activity were the glycopeptides, the streptogramin RP-59.500, and the @entity23782 (100% susceptibility). Eighty-seven percent of the OSSA and only 38% of the ORSA isolates were susceptible to @entity2177 (MIC50 0.25 microgram/mL and > 4 micrograms/mL, respectively). Cross-resistance among @entity2887 were noted even for the experimental drugs. Two @entity2887 remained active against @entity2177 -resistant isolates, @entity46663 and WIN-57.273. However, the @entity2177 -resistant isolates had MICs eight-to 64-fold higher than the @entity2177 -susceptible isolates, suggesting that the MICs may continue to increase when these @entity2887 become commercially available. CONCLUSION: Our results showed a high rate of antimicrobial resistance among @entity794 from the Brazilian hospitals. Very few drugs can still be used for the treatment of @entity1793 .

[Sensitivity pattern of 117 clinical isolates of XXXX from 12 hospitals].

@entity48094 :: ('MESH:D006020', 'Chemical') :: ['glycopeptides'] @entity46663 :: ('MESH:C057477', 'Chemical') :: ['clinafloxacin'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus'] @entity7660 :: ('MESH:D047090', 'Chemical') :: ['beta-lactams'] @entity2177 :: ('MESH:D002939', 'Chemical') :: ['ciprofloxacin'] @entity6101 :: ('MESH:D010068', 'Chemical') :: ['oxacillin'] @entity2887 :: ('MESH:D024841', 'Chemical') :: ['fluoroquinolones'] @entity23782 :: ('MESH:D016712', 'Chemical') :: ['mupirocin'] @entity7187 :: ('MESH:D018942', 'Chemical') :: ['macrolides'] @entity581 :: ('MESH:D000617', 'Chemical') :: ['aminoglycosides'] @entity1793 :: ('MESH:D013203', 'Disease') :: ['staphylococcal infections'] @entity35995 :: ('MESH:D055231', 'Chemical') :: ['lincosamides']
@entity794 :: (1280,Species) :: ['Staphylococcus aureus']
